Search Results
Your search for The ASCO Post matches 139 pages
Showing 101 - 139Long-Term Use of Hormonal Contraceptives Could Lead to Increased Risk of Brain Tumors
Taking a hormonal contraceptive for at least 5 years is associated with a possible increase in women’s risk of developing a glioma, according to a study by Andersen et al published in the British Journal of Clinical Pharmacology. Study Details While little is known about the causes of...
ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors
A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...
FDA Approves Lanreotide Injection for Gastroenteropancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) today approved lanreotide (Somatuline Depot Injection) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. Lanreotide was previously approved for...
Immune Checkpoint Inhibitors May Work in Brain Cancers
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today at the ESMO Symposium on Immuno-Oncology 2014 in Geneva (Abstract 1O). The novel research shows that brain metastases of tumor infiltrating lymphocytes, providing an immunoactive...
Molecular Tumor Markers Could Reveal New Therapeutic Targets for Lung Cancer Treatment
Analysis of 607 small cell lung cancer (SCLC) tumors and neuroendocrine tumors identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented at the 2014 Chicago Multidisciplinary...
FDA Grants Orphan Drug Designation to DNX-2401 for Malignant Glioma
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DNAtrix’s DNX-2401, a conditionally-replicative oncolytic adenovirus for malignant glioma. Glioma is the most common form of primary brain cancer, the treatment of which remains a significant unmet medical...
ESMO 2014: Everolimus Improves Overall Survival in Patients With Advanced Pancreatic Neuroendocrine Tumors
In a phase III trial, treatment with everolimus (Afinitor) resulted in a median overall survival of over 3 and a half years in patients with well-differentiated and progressive pancreatic neuroendocrine tumors, representing what the study authors called a "clinically important" although not...
Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and...
FDA Grants Orphan Drug Designation to Bivalent Vaccine for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MabVax Therapeutics’ vaccine for the treatment of relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment. The bivalent vaccine is intended to...
FDA Grants Priority Review to Lanreotide Injection for Gastroenteropancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to Ipsen’s supplemental New Drug Application (sNDA) for the somatostatin analog lanreotide (Somatuline Depot) 120 mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors. The FDA...
Early Study Identifies Tumor-Suppressor Gene, Potential Therapy for Medulloblastoma
An international, multi-institutional research group led by scientists at the Cancer and Blood Diseases Institute (CBDI) at Cincinnati Children’s Hospital Medical Center has identified a novel molecular pathway that causes an aggressive form of medulloblastoma, The study, reported by He et al ...
Investigational Compound ABT-414 Receives Orphan Drug Designation for Glioblastoma Multiforme
The U.S. Food and Drug Administration has granted orphan drug designation to AbbVie’s investigational compound ABT-414, which is being evaluated for safety and efficacy in patients with glioblastoma multiforme. ABT-414 is an investigational anti-EGFR (epidermal growth factor receptor)...
Lanreotide Significantly Prolongs Progression-Free Survival in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Although somatostatin analogs are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors, data on their antitumor effects are limited. In the phase III CLARINET trial reported in The New England Journal of Medicine, Caplin et al found that somatostatin...
Brain Tumor Invasion Along Blood Vessels May Lead to New Cancer Treatments, Preclinical Study Suggests
Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain’s protective barrier, preclinical study published in Nature Communications indicated. The finding by Watkins et al could ultimately lead to new ways to bring about the ...
Brain Tumor Risk Greater in Women Who Begin Menstruation at Older Age, Study Reports
Women who begin menstruation at an older age have a significantly increased risk of developing a brain tumor, a Moffitt Cancer Center study shows. The results are part of a large multicenter study to determine potential risk factors associated with the development of glioma and meningioma. The...
ASCO 2014: Addition of Chemotherapy to Radiotherapy Improves Survival in Low-Grade Glioma
In a long-term follow-up analysis of RTOG 9802, the addition of PCV (procarbazine [Matulane], lomustine [CeeNu], and vincristine) to radiotherapy prolonged both progression-free survival and overall survival in adult patients with low-grade glioma. The findings were reported at the 2014 ASCO Annual ...
Gene Sequencing Project Discovers Mutations Tied to High-Grade Gliomas in Young Children
The St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric high-grade gliomas. The findings by Wu et al were published in Nature Genetics and may lead to improved outcomes for children with these brain...
Researchers Identify Transcription Factors Distinguishing Glioblastoma Stem Cells
The activity of four transcription factors appears to distinguish the small proportion of glioblastoma cells responsible for the aggressiveness and treatment resistance of the deadly brain tumor. The findings by Suvà et al, published online in Cell, support the importance of epigenetics in...
Deep, Integrated Genomic Analysis Reclassifies Lower-Grade Brain Tumors
Using comprehensive genomic analysis, researchers have sorted low-grade brain tumors into three categories, one of which has the molecular hallmarks and shortened survival of glioblastoma multiforme, the most lethal of brain tumors. The findings were reported at the American Association for Cancer...
Pemetrexed and Gemcitabine Show Promise Against Aggressive Childhood Brain Tumor
The quest to improve survival of children with a high-risk brain tumor has led investigators at St. Jude Children's Research Hospital to two drugs already used to treat adults with breast, pancreatic, lung, and other cancers. The study by Morfouace at al was published today in Cancer Cell....
Study Identifies Possible New Target for Future Glioblastoma Drugs
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by Yan et al published in Cancer Research. The findings show that high levels of the enzyme PRMT5...
Study Identifies Common Driver of a Childhood Brain Tumor
The St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that the alteration drives tumor development. The findings were published online in...
Optimized Radiation Treatment Schedule for Glioblastoma May Extend Survival
An altered radiation treatment schedule for glioblastoma, the most common and lethal form of brain cancer, extended the survival period of mice with the disease, according to a new study published in Cell. Because the research involved mice, the study does not recommend a specific new schedule for...
Combination Capecitabine/Temozolomide Appears Highly Effective in Patients With Treatment-Resistant Neuroendocrine Tumors
Interim results from an ongoing phase II clinical trial in patients with various types of advanced neuroendocrine tumors show that a new chemotherapy combination of capecitabine and temozolomide either stalled disease progression or shrank tumors in 95% of patients whose disease worsened after...
Imaging Studies May Predict Tumor Response to Antiangiogenic Drugs
Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with antiangiogenic drugs and which will not. In a report published online in PNAS, researchers studied patients with newly diagnosed glioblastoma who were treated with the antiangiogenic agent...
Researchers Identify Potential New Drug for Inherited Cancer
Scientists from The Scripps Research Institute have identified a new drug candidate for an inherited form of cancer with no known cure. The new study showed the drug candidate—known as FRAX97—slowed the proliferation and progression of tumor cells in animal models of neurofibromatosis...
ASTRO: Younger Adults With a Limited Number of Brain Metastases Have Improved Overall Survival After Stereotactic Radiosurgery Alone
When treated with stereotactic radiosurgery that is not combined with whole-brain radiotherapy, adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented on Sunday, September 22, at the American Society for Radiation...
ASTRO: Proton Therapy Yields Encouraging Outcomes for Pediatric Brain Tumor Patients
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented on Sunday, September 22, at the American Society for Radiation Oncology’s 55th Annual Meeting...
New Laser-Based Tool Could Dramatically Improve the Accuracy of Brain Tumor Surgery
A new laser-based technology may make brain tumor surgery much more accurate, allowing surgeons to tell cancer tissue from normal brain at the microscopic level while they are operating, and avoid leaving behind cells that could spawn a new tumor. In a new paper published in Science Translational...
Brain Cancer Survival Improved Following FDA Approval of Bevacizumab, Mayo Study Finds
A new population-based study has found that patients with glioblastoma who died in 2010, after the FDA approval of bevacizumab (Avastin), had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of brain...
New MRI Technique Reveals Brain Tumor Response to Antiangiogenesis Therapy
A new way of analyzing data acquired in magnetic resonance imaging (MRI) appears to be able to identify whether or not tumors are responding to antiangiogenesis therapy, which may help physicians determine the most appropriate treatments for patients. In a report published online in Nature...
Study Suggests Neural Stem Cells May Regenerate After Radiation Therapy
Scientists have long believed that healthy brain cells, once damaged by radiation designed to kill brain tumors, cannot regenerate. But new research in mice suggests that neural stem cells, the body's source of new brain cells, are resistant to radiation, and can be roused from a hibernation-like...
Study Reveals Genes That Drive Glioblastoma
A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common—and most aggressive—form of brain cancer in adults. The study was published online...
Digital PCR Technology Detects Brain Tumor–associated Mutation in Cerebrospinal Fluid
Researchers at Massachusetts General Hospital have used digital versions of a standard molecular biology tool to detect a common tumor-associated mutation in the cerebrospinal fluid of patients with brain tumors. In a report published in Molecular Therapy – Nucleic Acids, the...
Virus Combination Effective Against Temozolomide-resistant Glioblastoma Multiforme
A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to new research published in Neuro-Oncology. Study lead author Peter A. Forsyth, MD, Chair of the Neuro-oncology Program at Moffitt ...
Metabolic Molecule Drives Growth of High-grade Glioma
A study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) has identified an abnormal metabolic pathway that drives cancer cell growth in a particular glioblastoma...
Cytomegalovirus Might Speed Brain Cancer Growth
A study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and Dana-Farber Cancer Institute suggests that cytomegalovirus, a virus that infects most adults in the United...
ASCO 2013: Adding Bevacizumab to Standard First-line Chemoradiation for Glioblastoma Does Not Improve Overall Survival
A randomized phase III study found no improvement in overall survival after the addition of bevacizumab (Avastin) to standard first-line chemoradiation for glioblastoma. Patients who received bevacizumab also experienced more side effects compared to those treated with chemoradiation alone. The...
New Minimally Invasive, MRI-guided Laser Treatment for Glioblastoma Found to Be Promising in Study
The NeuroBlate Thermal Therapy System provides a new, safe, and minimally invasive procedure for treating recurrent glioblastoma, according to the first-in-human study of the system. The study, published online today in the Journal of Neurosurgery, was written by lead author Andrew Sloan, MD,...
